To further interrupt the cancer-promoting functions of Ephrin A1, we inhibited EGFR activation by EGFR tyrosine kinase inhibitor (TKI) erlotinib and then evaluated the function of Ephrin A1. The gene discussed is EGFR; the disease is cancer.